MYH9: The Cellular Engine Connecting Genetic Disorders and Cancer, a New Target for Precision Medicine
-
The Essential Cellular Machinery, MYH9 and NMIIA The MYH9 gene encodes the non-muscle myosin heavy chain IIA (NMIIA) protein, which plays a crucial role in cellular activities such as movement, division, and signal transmission. This protein is a vital component for cells to function properly.
-
The Dual-Faced Gene: MYH9-RD and Cancer MYH9 was previously known primarily as the cause of the rare genetic disorder MYH9-related disease (MYH9-RD). However, recent studies have revealed that this gene is also deeply involved in the development and progression of various cancers.
- Uncharted Territory: The role of MYH9 in cancer remains unclear, with its function varying depending on the type of cancer. Further research is needed to determine whether MYH9 promotes or inhibits cancer.
- Genetic Connection: The question of whether individuals with MYH9-related disorders are more susceptible to cancer or protected from it has become a topic of interest in the academic community.
- Next-Generation Therapeutic Strategies: Precision Targeting of MYH9 The research team proposes that targeting MYH9 could be a powerful approach for future cancer treatment.
-
Non-coding RNAs and RNA Interference (RNAi): Regulate MYH9 function at the gene expression level.
-
Small Molecule Drugs: Directly control protein activity to inhibit cancer cell migration and metastasis.
-
CRISPR-Based Gene Editing: Correct underlying genetic mutations to maximize therapeutic effects.
- Outlook: Expansion from Genetics to Oncology This review study comprehensively summarizes the structural characteristics and clinical associations of MYH9, providing a crucial milestone for establishing next-generation anti-cancer strategies tailored to individual genetic backgrounds.
The myosin heavy chain 9 (MYH9) gene encodes non-muscle myosin heavy chain IIA (NMIIA), a vital protein involved in fundamental cellular activities, including movement, cell division, and signal transmission. Mutations in MYH9 were initially linked to autosomal dominant disorders collectively termed MYH9-related diseases (MYH9-RD). In recent years, MYH9 has gained significant attention for its pivotal roles in various cancers. However, despite extensive research, its exact contributions to cancer progression remain incompletely understood. Targeting MYH9 through approaches such as non-coding RNAs, small molecules, or gene therapy presents a promising avenue for advancing cancer treatment. Additionally, the dual role of MYH9 in MYH9-RD and cancer raises the intriguing question: are individuals with MYH9 mutations predisposed to or protected from cancer? This review aims to present the structure, functional significance, and clinical associations of MYH9, with an emphasis on its contributions to MYH9-RD and cancer progression. Furthermore, it examines MYH9's regulatory interactions with non-coding RNAs and its potential applications as a therapeutic target, offering insights into strategies such as RNA interference and CRISPR-based gene editing for cancer treatment.
MYH9 is a key molecule connecting cancer and genetic disorders, and understanding its mechanisms can lead to the discovery of new therapeutic targets. Additionally, the social impact is significant, as individualized MYH9 variation status can be used to predict cancer risk or develop personalized prevention strategies.